Glenzocimab is a humanized monoclonal antibody fragment (fab) directed against the human platelet glycoprotein GPVI, and a novel antithrombotic drug developed by Acticor-Biotech.
Glenzocimab is being developed for use during the acute phase of ischemic stroke as an add-on therapy to thrombolysis, with or without mechanical thrombectomy.
Since 2024, glenzocimab is also evaluated in the treatment of Acute Myocardial Infarction within a partnership with the University of Birmingham.